Smith & Nephew plc (SNN)
NYSE: SNN · Real-Time Price · USD
33.48
+0.75 (2.29%)
At close: Dec 5, 2025, 4:00 PM EST
33.07
-0.41 (-1.22%)
After-hours: Dec 5, 2025, 7:25 PM EST
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 27, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| US Revenue | 3.26B | 3.12B |
Log In |
Log In |
Log In | Upgrade
|
| Other Established Markets Revenue | 1.80B | 1.71B |
Log In |
Log In |
Log In | Upgrade
|
| Total Established Markets Revenue | 5.05B | 4.83B |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue | 979.00M | 980.00M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | - | 5.81B |
Log In |
Log In |
Log In | Upgrade
|
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 27, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Knee Implants Revenue | 982.00M | 947.00M |
Log In |
Log In |
Log In | Upgrade
|
| Hip Implants Revenue | 628.00M | 619.00M |
Log In |
Log In |
Log In | Upgrade
|
| Other Reconstruction Revenue | 132.00M | 131.00M |
Log In |
Log In |
Log In | Upgrade
|
| Trauma & Extremities Revenue | 636.00M | 608.00M |
Log In |
Log In |
Log In | Upgrade
|
| Total Orthopaedics Revenue | 2.38B | 2.31B |
Log In |
Log In |
Log In | Upgrade
|
| Sports Medicine Joint Repair Revenue | 1.03B | 982.00M |
Log In |
Log In |
Log In | Upgrade
|
| Arthroscopic Enabling Technologies Revenue | 637.00M | 632.00M |
Log In |
Log In |
Log In | Upgrade
|
| ENT (Ear, Nose and Throat) Revenue | 218.00M | 210.00M |
Log In |
Log In |
Log In | Upgrade
|
| Total Sports Medicine & ENT Revenue | 1.89B | 1.82B |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Wound Care Revenue | 749.00M | 735.00M |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Wound Bioactives Revenue | 622.00M | 581.00M |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Wound Devices Revenue | 397.00M | 365.00M |
Log In |
Log In |
Log In | Upgrade
|
| Total Advanced Wound Management Revenue | 1.77B | 1.68B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | - | 5.81B |
Log In |
Log In |
Log In | Upgrade
|
Adjusted EBIT
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2019 |
| Orthopaedics Segment Profit | 265.00M |
Log In |
Log In |
Log In | Upgrade
|
| Sports Medicine & ENT Segment Profit | 437.00M |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Wound Management Segment Profit | 399.00M |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Other) | -444.00M |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 657.00M |
Log In |
Log In |
Log In | Upgrade
|